1. Home
  2. SKYE vs FINW Comparison

SKYE vs FINW Comparison

Compare SKYE & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • FINW
  • Stock Information
  • Founded
  • SKYE 2012
  • FINW 1999
  • Country
  • SKYE United States
  • FINW United States
  • Employees
  • SKYE N/A
  • FINW N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • FINW Commercial Banks
  • Sector
  • SKYE Health Care
  • FINW Finance
  • Exchange
  • SKYE Nasdaq
  • FINW Nasdaq
  • Market Cap
  • SKYE 172.9M
  • FINW 170.0M
  • IPO Year
  • SKYE N/A
  • FINW 2021
  • Fundamental
  • Price
  • SKYE $6.99
  • FINW $13.97
  • Analyst Decision
  • SKYE Strong Buy
  • FINW Buy
  • Analyst Count
  • SKYE 5
  • FINW 1
  • Target Price
  • SKYE $18.40
  • FINW $17.00
  • AVG Volume (30 Days)
  • SKYE 157.3K
  • FINW 12.7K
  • Earning Date
  • SKYE 08-09-2024
  • FINW 10-24-2024
  • Dividend Yield
  • SKYE N/A
  • FINW N/A
  • EPS Growth
  • SKYE N/A
  • FINW N/A
  • EPS
  • SKYE N/A
  • FINW 1.18
  • Revenue
  • SKYE N/A
  • FINW $67,148,000.00
  • Revenue This Year
  • SKYE N/A
  • FINW N/A
  • Revenue Next Year
  • SKYE N/A
  • FINW $13.35
  • P/E Ratio
  • SKYE N/A
  • FINW $11.71
  • Revenue Growth
  • SKYE N/A
  • FINW 3.24
  • 52 Week Low
  • SKYE $1.44
  • FINW $8.31
  • 52 Week High
  • SKYE $19.41
  • FINW $14.98
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 61.35
  • FINW 75.00
  • Support Level
  • SKYE $5.71
  • FINW $12.22
  • Resistance Level
  • SKYE $6.69
  • FINW $13.25
  • Average True Range (ATR)
  • SKYE 0.71
  • FINW 0.45
  • MACD
  • SKYE 0.15
  • FINW 0.07
  • Stochastic Oscillator
  • SKYE 81.71
  • FINW 87.10

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

Share on Social Networks: